Duloxetine Capsule, Delayed Release
Product Images NDC 71335-2017

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-2017). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier curve showing the proportion of patients with relapse over time (days) from randomization for Duloxetine versus placebo treatment groups. The x-axis represents time from randomization to relapse in days, and the y-axis represents the proportion of patients with relapse, ranging from 0 to 1. The Duloxetine group shows a lower relapse proportion compared to placebo over approximately 200 days.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60/120 mg once daily and placebo. The x-axis represents percent improvement in pain, while the y-axis shows the percentage of patients improved. Two lines depict patient response rates for duloxetine and placebo across various pain improvement levels.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A line graph showing the proportion of patients with relapse over time in days from randomization, comparing placebo and duloxetine treatments. The x-axis represents time from randomization to relapse (days) ranging from 0 to 300. The y-axis shows the proportion of patients with relapse from 0.0 to 1.0. The graph includes two lines: a dashed line for placebo with higher relapse proportions and a solid line for duloxetine with lower relapse proportions over time.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line chart displaying percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The chart compares treatment groups showing trends in pain improvement across different thresholds.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups. The x-axis shows percent improvement in pain from 0 to 100, and the y-axis shows percentage of patients improved from 0 to 100%. The data indicate higher patient improvement rates for both Duloxetine doses compared to placebo across the improvement scale.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph depicting the percentage of patients improved in relation to percent improvement in pain from baseline, comparing Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The x-axis represents percent improvement in pain, while the y-axis shows the percentage of patients improved. Both Duloxetine dosing groups show higher patient improvement percentages than placebo across most improvement levels.*

FDA Label Image

Figure6 (Duloxetine Fig6)

Line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at 120mg, 60mg, 20mg once daily doses compared to placebo. The graph depicts higher improvement percentages for all Duloxetine doses relative to placebo across varying levels of pain improvement.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved on the y-axis with percent improvement in pain from baseline (BOCF) on the x-axis. It shows two lines representing placebo and Duloxetine 60/120 mg once daily. The graph illustrates trends in patient improvement at various pain reduction thresholds.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg once daily and placebo groups. The graph shows two lines: one with diamond markers for Duloxetine and one with cross markers for placebo, plotted against percent improvement intervals from >0 to 100%.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure diagram of duloxetine hydrochloride showing the molecular framework of the active ingredient in the product.*

FDA Label Image

Label (Lbl713352017)

Label for Duloxetine DR 30 mg delayed-release capsule by Bryant Ranch Prepack, NDC 71335-2017. The label compares the product to Cymbalta 30 mg capsule by Ajanta Pharma Limited. It includes storage instructions (20°-25°C/68°-77°F), a caution for drowsiness, a lot number, expiration date placeholder, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.